Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19

Thomas J. Esparzaa The National Institute of Neurological Disorders and Stroke Intramural Research Program, Laboratory of Functional and Molecular Imaging, Bethesda, MD, USA;b Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, MD, USA;c Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USAView further author information

Yaozong Chend Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USAView further author information

Negin P. Martine Viral Vector Core, National Institute of Environmental Health Sciences, NIH/DHHS, NC, USA;f Neurobiology Laboratory, National Institute of Environmental Health Sciences, NIH/DHHS, NC, USAView further author information

Helle Bielefeldt-Ohmanng School of Chemistry & Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St Lucia, Qld, AustraliaView further author information

Richard A. Bowenh Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, USAView further author information

William D. Tolbertd Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USAView further author information

Marzena Pazgierd Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USACorrespondence[email protected]

https://orcid.org/0000-0003-0594-5057 View further author information

David L. Brodya The National Institute of Neurological Disorders and Stroke Intramural Research Program, Laboratory of Functional and Molecular Imaging, Bethesda, MD, USA;b Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, MD, USA;i Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, MD, USACorrespondence[email protected]
View further author information

show all

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date